Increased prevalence of apolipoprotein E4 in type V hyperlipoproteinemia.

G Ghiselli, …, R E Gregg, H B Brewer Jr


Type V hyperlipoproteinemia (HLP) is characterized clinically by hepatosplenomegaly, occasional eruptive xanthomas, and an increased incidence of pancreatitis. These patients have striking hypertriglyceridemia due to increased plasma chylomicron and very low density lipoprotein concentrations in the fasting state, without a deficiency of lipoprotein lipase or its activator protein, apolipoprotein (apo) C-II. ApoE, a protein constituent of triglyceride-rich lipoproteins, has been implicated in the receptor-mediated hepatic uptake of these particles. ApoE has three major alleles: E2, E3, and E4, and the products of these alleles are apoE2, apoE3, and apoE4, respectively. ApoE phenotypes were determined in 30 type V HLP patients as well as in 37 normal volunteers. Among the type V patients, 33.3% were noted to be homozygous, and 40.0% heterozygous for E4 (normal, 2.7 and 21.6%, respectively). These data suggest that apoE4 may play a role in the etiology of the hyperlipidemia in a significant number of type V HLP patients.
Increased Prevalence of Apolipoprotein E4 in Type V Hyperlipoproteinemia

G. Ghiselli, E. J. Schaefer, L. A. Zech, R. E. Gregg, and H. B. Brewer, Jr.,
Molecular Disease Branch, National Heart, Lung, and Blood Institute,
National Institutes of Health, Bethesda, Maryland 20205

ABSTRACT Type V hyperlipoproteinemia (HLP) is characterized clinically by hepatosplenomegalgy, occasional eruptive xanthomas, and an increased incidence of pancreatitis. These patients have striking hypertriglyceridemia due to increased plasma chylomicron and very low density lipoprotein concentrations in the fasting state, without a deficiency of lipoprotein lipase or its activator protein, apolipoprotein (apo) C-II. ApoE, a protein constituent of triglyceride-rich lipoproteins, has been implicated in the receptor-mediated hepatic uptake of these particles. ApoE has three major alleles: E3, E3, and E4, and the products of these alleles are apoE2, apoE3, and apoE4, respectively. ApoE phenotypes were determined in 30 type V HLP patients as well as in 37 normal volunteers. Among the type V patients, 33.3% were noted to be homozygous, and 40.0% heterozygous for E4 (normal, 27 and 21.6%, respectively). These data suggest that apoE4 may play a role in the etiology of the hyperlipidemia in a significant number of type V HLP patients.

INTRODUCTION

Apolipoprotein (apo) E is a major protein constituent of plasma very low density lipoproteins (VLDL)1 (1, 2). Studies in animals and man indicate that apoE may play a crucial role in the regulation of lipoprotein metabolism and is possibly involved in the atherogenic process (3). ApoE has been reported to be important in the receptor-mediated uptake by the liver of triglyceride-rich lipoproteins, especially chylomicron remnants (4–6). Isoelectrofocusing (IEF) of delipidated VLDL protein by polyacrylamide gel electrophoresis (PAGE) demonstrates the presence of three major apoE bands in man: E2, E3, and E4 (7, 8). These apoE bands differ in their isoelectric point due to arginine for cysteine substitutions at two positions in the polypeptide chain (9).

ApoE has been proposed to be inherited at a single genetic locus with three common alleles (8). The three gene products are designated as apoE2, apoE3, and apoE4. In the plasma of any given individual either one major apoE form is observed (homozygote) or two major forms are noted (heterozygote). A population study in central Germany revealed the following frequency of apoE phenotypes: E3 (58.9%), E3/4 (24.3%), E2/3 (13.1%), E4 (2.7%), and E2 (1.0%) (7, 10).2 A study of normal individuals in the United States yielded similar distributions except that E2/4 was seen in 3.3% of the subjects (8). Most patients with type III hyperlipoproteinemia (HLP) have been shown to have the E2 phenotype (7, 10), and apoE from type III HLP on plasma lipoproteins is degraded at a lower fractional catabolic rate than is normal apoE in normal and type III HLP subjects (11). Recently we have shown that type III HLP may also be due to apoE deficiency (12).

Plasma apoE concentrations have been shown to be increased in most patients with type III HLP and type V HLP (13–16). Type V patients may have hepatosplenomegalgy, lipemia retinalis, eruptive xanthomas, and pancreatitis (17). These patients have striking hy-

---

2 In this report apoE alleles are designated as E2, E3, and E4, and the gene products of these alleles are apoE2, apoE3, and apoE4, respectively. The six apoE genotypes are E2/E2, E2/E3, E2/E4, E3/E3, E3/E4, and E4/E4. The corresponding phenotypes, as determined by IEF PAGE, for homozygotes are E2, E3, and E4, and for heterozygotes E2/3, E2/4, and E3/4, respectively. The major apoE isoforms on IEF PAGE are designated as the E2, E3, and E4 bands.
pertriglyceridemia in the fasting state due to elevations of both chylomicrons and VLDL (17). The purpose of this study was to investigate apoE phenotypes in type V HLP patients. We observed a higher than expected prevalence of E4 homozygosity and heterozygosity, consistent with the concept that apoE<sub>4</sub> may play a role in the pathogenesis of type V HLP.

**METHODS**

30 type V hyperlipoproteinemic patients were selected from the dyslipoproteinemic patients attending the clinic of the Molecular Disease Branch at the National Institutes of Health. The mean age of these patients was 51±8 yr (mean±SD). Subjects were diagnosed as having type V hyperlipoproteinemia by the following criteria: (a) plasma triglyceride above 1,000 mg/dl, (b) chylomicrons and VLDL present in fasting plasma as determined by lipoprotein electrophoresis (18), (c) no evidence of lipoprotein lipase deficiency (19), and (d) no plasma apoC II deficiency (20). No patients had secondary causes of hyperlipidemia other than diabetes mellitus (40%) and obesity. Almost all patients were on low fat (20% of calories) diets when sampled for this study, and none were receiving medication known to affect plasma lipids except for diabetic subjects who required insulin. 37 normal subjects were also analyzed for the apoE phenotype. Their mean age was 27±4 yr.

Blood was obtained in 0.1% EDTA after an overnight fast, and the plasma was separated at 4°C in a refrigerated centrifuge. Plasma cholesterol and triglyceride levels were measured with a Technicon Auto Analyzer II (Technicon Instruments Corp., Tarrytown, NY) (18). VLDL were separated by ultracentrifugation at 1,006 g/ml at 39,000 rpm for 18 h at 4°C in Beckman 40.3 rotors (Beckman Instruments, Inc., Fullerton, CA), and the lipoprotein fractions were recovered by tube slicing (21). HDL cholesterol was measured after heparin-manganese precipitation of the 1,006 g/ml plasma infranate. Low density lipoprotein (LDL) cholesterol was calculated by subtraction of the HDL cholesterol from the 1,006 g/ml plasma infranate cholesterol value (18). VLDL, 1,006 g/ml infranate, and HDL cholesterol levels were determined by automated techniques as described for plasma. Lipoprotein electrophoresis for lipoprotein phenotyping was performed on the plasma and the 1,006-g/ml supernate and infranate (18).

VLDL were isolated by ultracentrifugation as previously described and washed a second time by the same technique. The isolated lipoproteins were desalted by passage through a Sephadex G-25 prepacked column (Pharmacia AB, Uppsala, Sweden) (6 x 1.5 cm), equilibrated, and eluted with 0.08% ammonium bicarbonate. VLDL were then lyophilized and delipidated with chloroform/methanol (3:1, vol/vol). VLDL apoproteins were solubilized in 8.6 M urea and 0.1 M Tris-HCl (pH 8.2) just before electrophoresis. Aliquots were assayed for the protein content by the Bradford method (22). Isoelectrofocusing of the VLDL apoE was performed on 7.5% polyacrylamide slab gels. Serva (Serva AB, Heidelberg, Federal Republic of Germany) ampholines were added to the acrylamide solution to produce a pH range between 4 and 6. 30 µg of VLDL apolipoproteins were loaded on the gels and electrofocused for 16 h at 250 V, with cooling of the electrophoretic cell at 4°C. Lower and upper buffers were 0.01 M phosphoric acid and 0.02 M sodium hydroxide, respectively. Gels were stained in 300 ml of 12.5% trichloroacetic acid containing 15 ml of Coomassie Blue G 250 (1% as stock solution) and preserved in 5% acetic acid. The major apoE isoforms electrofocused between pH 5.4 and 5.8 as determined by internal standards. The results from the slab gel isoelectrofocusing were confirmed by two-dimensional electrophoresis (8) in 25 of the 30 type V subjects and in 10 of the normal individuals.

**RESULTS**

Plasma lipid and lipoprotein cholesterol concentrations for the type V HLP subjects studied are shown in Table I, and the data are compared with those obtained for the normal population. Type V HLP patients had mean plasma triglyceride levels (1,640 mg/dl) and VLDL cholesterol concentrations (309 mg/dl) that were significantly (P < 0.01) higher than normal, and decreased HDL cholesterol values consistent with previous observations (23). The mean VLDL cholesterol/plasma triglyceride ratio in type V HLP was 0.19, similar to normal. The mean triglyceride level in our patients before institution of the low-fat (20% of total calories) diet was 3,024 mg/dl.

Six different isofrom patterns for apoE were observed. Their typical appearance on slab gel IEF are shown in Fig. 1. ApoE isofrom phenotype frequencies in type V HLP as compared with three normal populations are shown in Table II. 10 of the 30 type V

| Table I | Plasma Lipid and Lipoprotein Cholesterol Concentrations in Normal and Type V Hyperlipoproteinemic Subjects* |
|-----------------|-----------------|-----------------|-----------------|
| Subjects        | Plasma Cholesterol | Triglycerides    | VLDL            | LDL            | HDL            |
|                 | mg/dl            |                  | mg/dl           | mg/dl          | mg/dl          |
| Normal, n = 37  | 178±34           | 82±29            | 12±7            | 133±33         | 54±15          |
| Type V, n = 30  | 426±1311         | 1640±5371        | 309±2011        | 96±501         | 21±81          |

* Mean±SD.  
† Significantly different (P < 0.01) from normal as determined by t test analysis.

Apolipoprotein E<sub>4</sub> in Type V Hyperlipoproteinemia 475
subjects screened (33.3%) had the E4 phenotype, in striking contrast to that observed for normal subjects (2.7%). Over 50% of the normal population were found to have the E3 phenotype. In contrast only two of the 30 (6.7%) type V patients had this phenotype. In a normal population the following apoE allele frequencies were noted: E2, 9.5%; E3, 77.0%; and E4, 13.5%. Utermann et al. (7, 10) have reported for a population of 490 normal individuals the following apoE allele frequencies: E2, 7.6%; E3, 77.6%; and E4, 14.8%. Zannis and Breslow (8) have obtained similar results: 17.2%, 72.2%, and 10.6%, respectively. In this study of type V HLP subjects the allele frequency for E2 was 15.0%; for E3, 33.3%; and for E4, 51.7%. A significantly (P < 0.01) higher frequency of the E4 allele was therefore observed in type V patients. There was no significant difference in the lipid and lipoprotein levels of the type V patients having the E4 phenotype when compared with the other type V subjects. No sex differences in the allele frequencies in our patients or in normals (7, 10) have been observed. In addition, no significant differences in these frequencies were observed when diabetic and nondiabetic patients were compared.

FIGURE 1. Isoelectric focusing of VLDL apoproteins from plasma of patients with type V hyperlipoproteinemia. Lipoprotein isolation and delipidation was performed as described in the text. 30 μg of apo-VLDL were loaded in each well. Six different phenotypes are shown: (1) E5; (2) E4; (3) E4; (4) E5/5; (5) E3/4; and (6) E3/4. Only the gels showing apoH, the E4, E3, and E2 bands, and apoA-I are presented. Apoproteins have been identified by comparison with purified standards.

<table>
<thead>
<tr>
<th>ApoE phenotype nomenclature</th>
<th>ApoE phenotype frequency</th>
<th>Type V HLP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>apoE-ND/E4+</td>
<td>β-II</td>
<td>E4</td>
</tr>
<tr>
<td>apoE-N/E4+</td>
<td>α-II</td>
<td>E3/4</td>
</tr>
<tr>
<td>apoE-D/E4+</td>
<td>α-IV</td>
<td>E2/4</td>
</tr>
<tr>
<td>apoE-N/E4−</td>
<td>β-III</td>
<td>E3</td>
</tr>
<tr>
<td>apoE-ND/E4−</td>
<td>α-III</td>
<td>E2/3</td>
</tr>
<tr>
<td>apoE-D/E4−</td>
<td>β-IV</td>
<td>E2</td>
</tr>
</tbody>
</table>

* Nomenclature 1 refers to that used by Utermann et al. (7); 2 to that used by Zannis and Breslow (8), and 3 refers to the nomenclature used in this report.

† Phenotype frequencies for the population 1 have been calculated from the data presented by Utermann et al. (7) for a normal population studied in Germany. Phenotype frequencies for normal population 2 have been reported by Zannis and Breslow (8). Normal population 3 is that analyzed in this study.

‡ Normal population.

§ The number of the subjects studied is given in parentheses.

DISCUSSION

The molecular defect in type V HLP remains to be elucidated. These patients do not have a deficiency of lipoprotein lipase or apoC-II to account for their marked hypertriglyceridemia (19, 20). Similar to type III HLP, type V HLP is often not manifest until middle age (17), suggesting a role for environmental and hormonal factors as well as genetic abnormalities. Type V HLP has been noted to be familial in certain kindreds, and in addition, may be found in families with other forms of HLP such as type II and type IV (24, 25). Precise genetic patterns have not been determined, and it has been suggested that the type V HLP phenotype may be due to a number of different genetic defects (17). VLDL appears to be the most affected lipoprotein fraction in type V HLP. Metabolic studies indicate that these patients have both a threefold increase in synthesis rate as well as a decreased fractional catabolism of VLDL apoB (26). The functional importance of the apoE isoforms in the metabolism of triglyceride-rich lipoproteins is suggested by the fact that type III HLP has been associated either with apoE deficiency (12) or the E2 phenotype (10). In patients with undetectable plasma apoE there is
accumulation of chylomicron remnants containing apoB-48 and apoA-IV within VLDL, IDL, and LDL density fractions (12). Lipoproteins containing apoE2 have a reduced uptake by the perfused rat liver (6) and have a delayed clearance in man when compared with lipoproteins containing apoE3 (11). These data indicate that the apoE and its isoforms may be of important clinical significance and may affect the catabolism of the triglyceride-rich lipoproteins in man. Our results are consistent with the concept that the presence of the E4 allele may be a genetic factor that predisposes or contributes to the development of type V HLP. A much higher frequency of this apoE phenotype was observed in the type V HLP patients studied than that noted in normal populations (7, 8, 10). However, only a portion of the patients studied had this phenotype. This suggests that type V HLP may be due to several different molecular defects. The data presented in this report indicate that one form of apoE (apoE4) may be important in the pathogenesis of type V HLP.

REFERENCES


Apolipoprotein E4 in Type V Hyperlipoproteinemia